168 related articles for article (PubMed ID: 33837087)
1. A cell-based screening method using an intracellular antibody for discovering small molecules targeting the translocation protein LMO2.
Bery N; Bataille CJR; Russell A; Hayes A; Raynaud F; Milhas S; Anand S; Tulmin H; Miller A; Rabbitts TH
Sci Adv; 2021 Apr; 7(15):. PubMed ID: 33837087
[TBL] [Abstract][Full Text] [Related]
2. Competitive SPR using an intracellular anti-LMO2 antibody identifies novel LMO2-interacting compounds.
Canning P; Bataille C; Bery N; Milhas S; Hayes A; Raynaud F; Miller A; Rabbitts T
J Immunol Methods; 2021 Jul; 494():113051. PubMed ID: 33794223
[TBL] [Abstract][Full Text] [Related]
3. Conformational flexibility of the oncogenic protein LMO2 primes the formation of the multi-protein transcription complex.
Sewell H; Tanaka T; El Omari K; Mancini EJ; Cruz A; Fernandez-Fuentes N; Chambers J; Rabbitts TH
Sci Rep; 2014 Jan; 4():3643. PubMed ID: 24407558
[TBL] [Abstract][Full Text] [Related]
4. LMO2 at 25 years: a paradigm of chromosomal translocation proteins.
Chambers J; Rabbitts TH
Open Biol; 2015 Jun; 5(6):150062. PubMed ID: 26108219
[TBL] [Abstract][Full Text] [Related]
5. Pan RAS-binding compounds selected from a chemical library by inhibiting interaction between RAS and a reduced affinity intracellular antibody.
Tanaka T; Thomas J; Van Montfort R; Miller A; Rabbitts T
Sci Rep; 2021 Jan; 11(1):1712. PubMed ID: 33462327
[TBL] [Abstract][Full Text] [Related]
6. LMO2 attenuates tumor growth by targeting the Wnt signaling pathway in breast and colorectal cancer.
Liu Y; Huang D; Wang Z; Wu C; Zhang Z; Wang D; Li Z; Zhu T; Yang S; Sun W
Sci Rep; 2016 Oct; 6():36050. PubMed ID: 27779255
[TBL] [Abstract][Full Text] [Related]
7. LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era.
Cerhan JR; Natkunam Y; Morton LM; Maurer MJ; Asmann Y; Habermann TM; Vasef MA; Cozen W; Lynch CF; Allmer C; Slager SL; Lossos IS; Chanock SJ; Rothman N; Hartge P; Dogan A; Wang SS
Leuk Lymphoma; 2012 Jun; 53(6):1105-12. PubMed ID: 22066713
[TBL] [Abstract][Full Text] [Related]
8. Single domain intracellular antibodies from diverse libraries: emphasizing dual functions of LMO2 protein interactions using a single VH domain.
Tanaka T; Sewell H; Waters S; Phillips SE; Rabbitts TH
J Biol Chem; 2011 Feb; 286(5):3707-16. PubMed ID: 20980262
[TBL] [Abstract][Full Text] [Related]
9. PML-RARα interferes with erythropoiesis by repressing LMO2 in acute promyelocytic leukaemia.
Yang X; Tan Y; Wang P; Zhang H; Zhao M; Zhao X; Wang K
J Cell Mol Med; 2018 Dec; 22(12):6275-6284. PubMed ID: 30320491
[TBL] [Abstract][Full Text] [Related]
10. High expression of LMO2 in Hodgkin, Burkitt and germinal center diffuse large B cell lymphomas.
Shams TM
J Egypt Natl Canc Inst; 2011 Dec; 23(4):147-53. PubMed ID: 22776842
[TBL] [Abstract][Full Text] [Related]
11. LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas.
Colomo L; Vazquez I; Papaleo N; Espinet B; Ferrer A; Franco C; Comerma L; Hernandez S; Calvo X; Salar A; Climent F; Mate JL; Forcada P; Mozos A; Nonell L; Martinez A; Carrio A; Costa D; Dlouhy I; Salaverria I; Martin-Subero JI; Lopez-Guillermo A; Valera A; Campo E;
Am J Surg Pathol; 2017 Jul; 41(7):877-886. PubMed ID: 28288039
[TBL] [Abstract][Full Text] [Related]
12. LMO2 Enhances Lamellipodia/Filopodia Formation in Basal-Type Breast Cancer Cells by Mediating ARP3-Profilin1 Interaction.
Liu Y; Wu C; Zhu T; Sun W
Med Sci Monit; 2017 Feb; 23():695-703. PubMed ID: 28170369
[TBL] [Abstract][Full Text] [Related]
13. Angiopoietin-2 is a direct transcriptional target of TAL1, LYL1 and LMO2 in endothelial cells.
Deleuze V; El-Hajj R; Chalhoub E; Dohet C; Pinet V; Couttet P; Mathieu D
PLoS One; 2012; 7(7):e40484. PubMed ID: 22792348
[TBL] [Abstract][Full Text] [Related]
14. Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody.
Agostinelli C; Paterson JC; Gupta R; Righi S; Sandri F; Piccaluga PP; Bacci F; Sabattini E; Pileri SA; Marafioti T
Histopathology; 2012 Jul; 61(1):33-46. PubMed ID: 22394247
[TBL] [Abstract][Full Text] [Related]
15. Enforced expression of E47 has differential effects on Lmo2-induced T-cell leukemias.
Goodings C; Tripathi R; Cleveland SM; Elliott N; Guo Y; Shyr Y; Davé UP
Leuk Res; 2015 Jan; 39(1):100-9. PubMed ID: 25499232
[TBL] [Abstract][Full Text] [Related]
16. [Regulation of E-cadherin promoter activity by LMO2 impact on the progression and metastasis of prostate cancer].
Peng X; Ye Z; Gao Y
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2013 Sep; 29(5):385-9. PubMed ID: 24386807
[TBL] [Abstract][Full Text] [Related]
17. LMO2 is required for TAL1 DNA binding activity and initiation of definitive haematopoiesis at the haemangioblast stage.
Stanulovic VS; Cauchy P; Assi SA; Hoogenkamp M
Nucleic Acids Res; 2017 Sep; 45(17):9874-9888. PubMed ID: 28973433
[TBL] [Abstract][Full Text] [Related]
18. Activation of the
Rahman S; Magnussen M; León TE; Farah N; Li Z; Abraham BJ; Alapi KZ; Mitchell RJ; Naughton T; Fielding AK; Pizzey A; Bustraan S; Allen C; Popa T; Pike-Overzet K; Garcia-Perez L; Gale RE; Linch DC; Staal FJT; Young RA; Look AT; Mansour MR
Blood; 2017 Jun; 129(24):3221-3226. PubMed ID: 28270453
[TBL] [Abstract][Full Text] [Related]
19. Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL.
McCormack MP; Shields BJ; Jackson JT; Nasa C; Shi W; Slater NJ; Tremblay CS; Rabbitts TH; Curtis DJ
Blood; 2013 Sep; 122(12):2093-103. PubMed ID: 23926305
[TBL] [Abstract][Full Text] [Related]
20. Novel non-TCR chromosome translocations t(3;11)(q25;p13) and t(X;11)(q25;p13) activating LMO2 by juxtaposition with MBNL1 and STAG2.
Chen S; Nagel S; Schneider B; Kaufmann M; Meyer C; Zaborski M; Kees UR; Drexler HG; MacLeod RA
Leukemia; 2011 Oct; 25(10):1632-5. PubMed ID: 21647158
[No Abstract] [Full Text] [Related]
[Next] [New Search]
